These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 29934407)

  • 1. Behavioral Symptoms in Premanifest Huntington Disease Correlate with Reduced Frontal CB
    Ceccarini J; Ahmad R; Van de Vliet L; Casteels C; Vandenbulcke M; Vandenberghe W; Van Laere K
    J Nucl Med; 2019 Jan; 60(1):115-121. PubMed ID: 29934407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regional changes in the type 1 cannabinoid receptor are associated with cognitive dysfunction in Parkinson's disease.
    Ceccarini J; Casteels C; Ahmad R; Crabbé M; Van de Vliet L; Vanhaute H; Vandenbulcke M; Vandenberghe W; Van Laere K
    Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2348-2357. PubMed ID: 31342135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuropsychiatric symptoms are very common in premanifest and early stage Huntington's Disease.
    Martinez-Horta S; Perez-Perez J; van Duijn E; Fernandez-Bobadilla R; Carceller M; Pagonabarraga J; Pascual-Sedano B; Campolongo A; Ruiz-Idiago J; Sampedro F; Landwehrmeyer GB; ; Kulisevsky J
    Parkinsonism Relat Disord; 2016 Apr; 25():58-64. PubMed ID: 26898966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic and type 1 cannabinoid receptor imaging of a transgenic rat model in the early phase of Huntington disease.
    Casteels C; Vandeputte C; Rangarajan JR; Dresselaers T; Riess O; Bormans G; Maes F; Himmelreich U; Nguyen H; Van Laere K
    Exp Neurol; 2011 Jun; 229(2):440-9. PubMed ID: 21459091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Widespread decrease of type 1 cannabinoid receptor availability in Huntington disease in vivo.
    Van Laere K; Casteels C; Dhollander I; Goffin K; Grachev I; Bormans G; Vandenberghe W
    J Nucl Med; 2010 Sep; 51(9):1413-7. PubMed ID: 20720046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Striatal hypometabolism in premanifest and manifest Huntington's disease patients.
    López-Mora DA; Camacho V; Pérez-Pérez J; Martínez-Horta S; Fernández A; Sampedro F; Montes A; Lozano-Martínez GA; Gómez-Anson B; Kulisevsky J; Carrió I
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2183-2189. PubMed ID: 27349245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal changes in the fronto-striatal network are associated with executive dysfunction and behavioral dysregulation in Huntington's disease: 30 months IMAGE-HD data.
    Domínguez D JF; Poudel G; Stout JC; Gray M; Chua P; Borowsky B; Egan GF; Georgiou-Karistianis N
    Cortex; 2017 Jul; 92():139-149. PubMed ID: 28482181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dorsolateral prefrontal cortex dysfunction in presymptomatic Huntington's disease: evidence from event-related fMRI.
    Wolf RC; Vasic N; Schönfeldt-Lecuona C; Landwehrmeyer GB; Ecker D
    Brain; 2007 Nov; 130(Pt 11):2845-57. PubMed ID: 17855375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Linking white matter and deep gray matter alterations in premanifest Huntington disease.
    Faria AV; Ratnanather JT; Tward DJ; Lee DS; van den Noort F; Wu D; Brown T; Johnson H; Paulsen JS; Ross CA; Younes L; Miller MI;
    Neuroimage Clin; 2016; 11():450-460. PubMed ID: 27104139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential Changes in Functional Connectivity of Striatum-Prefrontal and Striatum-Motor Circuits in Premanifest Huntington's Disease.
    Kronenbuerger M; Hua J; Bang JYA; Ultz KE; Miao X; Zhang X; Pekar JJ; van Zijl PCM; Duan W; Margolis RL; Ross CA
    Neurodegener Dis; 2019; 19(2):78-87. PubMed ID: 31412344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between cerebral cannabinoid 1 receptor availability and body mass index in patients with food intake disorders and healthy subjects: a [(18)F]MK-9470 PET study.
    Ceccarini J; Weltens N; Ly HG; Tack J; Van Oudenhove L; Van Laere K
    Transl Psychiatry; 2016 Jul; 6(7):e853. PubMed ID: 27404285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: a multimodal imaging study.
    Politis M; Pavese N; Tai YF; Kiferle L; Mason SL; Brooks DJ; Tabrizi SJ; Barker RA; Piccini P
    Hum Brain Mapp; 2011 Feb; 32(2):258-70. PubMed ID: 21229614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prodromal Huntington disease as a model for functional compensation of early neurodegeneration.
    Malejko K; Weydt P; Süßmuth SD; Grön G; Landwehrmeyer BG; Abler B
    PLoS One; 2014; 9(12):e114569. PubMed ID: 25541992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early decrease of type 1 cannabinoid receptor binding and phosphodiesterase 10A activity in vivo in R6/2 Huntington mice.
    Ooms M; Rietjens R; Rangarajan JR; Vunckx K; Valdeolivas S; Maes F; Himmelreich U; Fernandez-Ruiz J; Bormans G; Van Laere K; Casteels C
    Neurobiol Aging; 2014 Dec; 35(12):2858-2869. PubMed ID: 25018107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cortical thickness, stance control, and arithmetic skill: An exploratory study in premanifest Huntington disease.
    Nanetti L; Contarino VE; Castaldo A; Sarro L; Bachoud-Levi AC; Giavazzi M; Frittoli S; Ciammola A; Rizzo E; Gellera C; Bruzzone MG; Taroni F; Grisoli M; Mariotti C
    Parkinsonism Relat Disord; 2018 Jun; 51():17-23. PubMed ID: 29496355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cognition in Huntington's disease in manifest, premanifest and converting gene carriers over ten years.
    Hart EP; Dumas EM; Giltay EJ; Middelkoop HA; Roos RA
    J Huntingtons Dis; 2013; 2(2):137-47. PubMed ID: 25063511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synaptic Damage and Its Clinical Correlates in People With Early Huntington Disease: A PET Study.
    Delva A; Michiels L; Koole M; Van Laere K; Vandenberghe W
    Neurology; 2022 Jan; 98(1):e83-e94. PubMed ID: 34663644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The phosphodiesterase 10 positron emission tomography tracer, [18F]MNI-659, as a novel biomarker for early Huntington disease.
    Russell DS; Barret O; Jennings DL; Friedman JH; Tamagnan GD; Thomae D; Alagille D; Morley TJ; Papin C; Papapetropoulos S; Waterhouse RN; Seibyl JP; Marek KL
    JAMA Neurol; 2014 Dec; 71(12):1520-8. PubMed ID: 25322077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gender-dependent increases with healthy aging of the human cerebral cannabinoid-type 1 receptor binding using [(18)F]MK-9470 PET.
    Van Laere K; Goffin K; Casteels C; Dupont P; Mortelmans L; de Hoon J; Bormans G
    Neuroimage; 2008 Feb; 39(4):1533-41. PubMed ID: 18077184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reciprocal alterations in cortical cannabinoid receptor 1 binding relative to protein immunoreactivity and transcript levels in schizophrenia.
    Volk DW; Eggan SM; Horti AG; Wong DF; Lewis DA
    Schizophr Res; 2014 Oct; 159(1):124-9. PubMed ID: 25107849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.